VolitionRx Increases $7.5 Million At-the-Market Offering to Up to $30 Million

In August Stradling represented VolitionRx, a company which, through its subsidiaries, is developing and commercializing simple, easy-to-use, costeffective blood tests to diagnose and monitor a range of diseases, including some cancers, diseases associated with NETosis and sepsis, with the increase of a previously launched At-the-Market Offering to up to $30 Million with JonesTrading Institutional Services LLC.